In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01132417|
Recruitment Status : Suspended (researchers delay)
First Posted : May 28, 2010
Last Update Posted : June 23, 2011
|Condition or disease||Intervention/treatment|
|Infections, Bacterial||Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|
Study Phase Definition: Phase of investigation, as defined by the US FDA for trials involving investigational new drugs. Select only one.
N/A: for trials without phases Observational Study Design Case-control: group of individuals with specific characteristics (e.g., conditions or exposures) compared to group(s) with different Time Perspective Cross-sectional: observations or measurements made at a single point in time, usually at subject enrollment Biospecimen Retention - select one Samples Without DNA - samples retained, with no potential for DNA extraction from any retained samples (e.g., fixed tissue, plasma) Biospecimen Description
Sputum, whole blood, urine, tissue Enrollment
Single group study Number of Groups/Cohorts Definition: Number of study groups/cohorts. Enter 1 for a single-group study. Many observational studies have one group/cohort; case control studies typically have two.
One study group, anticipated samples in the rang of 400-500 samples 8. Arms, Groups and Interventions N/L Group/Cohort Label
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Observational Model:||Case Control|
|Official Title:||In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||June 2012|
|Estimated Study Completion Date :||July 2012|
|Multidrug resistant (MDR)bacterial strains||
Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01132417
|King Faisal Univrsity, Departmentof Microbiology and Immunology,, dammam branh|
|Dammam, Eastern, Saudi Arabia, 31451|
|Principal Investigator:||Asim E Ltayeb Diab, MD, Ph D||Assist. Professor and Consultant Microbiologist|